These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
446 related articles for article (PubMed ID: 34735975)
21. N6-methylandenosine-related lncRNAs play an important role in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma. Hu Y; Chen Y Sci Rep; 2021 Sep; 11(1):17844. PubMed ID: 34497315 [TBL] [Abstract][Full Text] [Related]
22. N6-Methyladenosine-Related LncRNAs Are Potential Remodeling Indicators in the Tumor Microenvironment and Prognostic Markers in Osteosarcoma. Wu Z; Zhang X; Chen D; Li Z; Wu X; Wang J; Deng Y Front Immunol; 2021; 12():806189. PubMed ID: 35095893 [TBL] [Abstract][Full Text] [Related]
23. Analysis of m Wu X; Wang S; Wu X; Chen Q; Cheng J; Qi Z J Cancer; 2024; 15(7):2045-2065. PubMed ID: 38434979 [No Abstract] [Full Text] [Related]
24. Identification of Ferroptosis-Associated Long Noncoding RNA Prognostic Model and Tumor Immune Microenvironment in Thyroid Cancer. Lin Y; Gan F; He X; Deng H; Li Y J Immunol Res; 2022; 2022():5893998. PubMed ID: 35915656 [TBL] [Abstract][Full Text] [Related]
25. Construction of an N6-methyladenosine lncRNA- and immune cell infiltration-related prognostic model in colorectal cancer. Yu ZL; Zhu ZM Protoplasma; 2022 Jul; 259(4):1029-1045. PubMed ID: 34734333 [TBL] [Abstract][Full Text] [Related]
26. Comprehensive Analysis of N6-Methyladenosine-Related lncRNA Signature for Predicting Prognosis and Immune Cell Infiltration in Patients with Colorectal Cancer. Zhao Z; Yang YB; Li XY; Li XG; Chu XD; Lin ZB; Zhang YR; Guo YG; Ding H; Pan YL; Wang L; Pan JH Dis Markers; 2021; 2021():8686307. PubMed ID: 34745388 [TBL] [Abstract][Full Text] [Related]
27. M6A-related lncRNAs predict clinical outcome and regulate the tumor immune microenvironment in hepatocellular carcinoma. Chen B; Yang Z; Lang Z; Tao Q; Zhang R; Zhan Y; Xu X; Zhu K; Zheng J; Yu Z; Yu S BMC Cancer; 2022 Aug; 22(1):867. PubMed ID: 35941582 [TBL] [Abstract][Full Text] [Related]
28. m6A-immune-related lncRNA prognostic signature for predicting immune landscape and prognosis of bladder cancer. Feng ZH; Liang YP; Cen JJ; Yao HH; Lin HS; Li JY; Liang H; Wang Z; Deng Q; Cao JZ; Huang Y; Wei JH; Luo JH; Chen W; Chen ZH J Transl Med; 2022 Oct; 20(1):492. PubMed ID: 36309694 [TBL] [Abstract][Full Text] [Related]
29. The prognostic value and immune landscaps of m6A/m5C-related lncRNAs signature in the low grade glioma. Li R; Chen H; Li C; Qi Y; Zhao K; Wang J; You C; Huang H BMC Bioinformatics; 2023 Jul; 24(1):274. PubMed ID: 37403043 [TBL] [Abstract][Full Text] [Related]
30. Identification of Nine M6A-Related Long Noncoding RNAs as Prognostic Signatures Associated with Oxidative Stress in Oral Cancer Based on Data from The Cancer Genome Atlas. Shan L; Lu Y; Song Y; Zhu X; Xiang CC; Zuo ED; Cheng X Oxid Med Cell Longev; 2022; 2022():9529814. PubMed ID: 35910847 [TBL] [Abstract][Full Text] [Related]
31. A cell cycle-related lncRNA signature predicts the progression-free interval in papillary thyroid carcinoma. Li S; Ran MY; Qiao H Front Endocrinol (Lausanne); 2023; 14():1110987. PubMed ID: 36923215 [TBL] [Abstract][Full Text] [Related]
32. Comprehensive characterization of tumor microenvironment and m6A RNA methylation regulators and its effects on PD-L1 and immune infiltrates in cervical cancer. Ji H; Zhang JA; Liu H; Li K; Wang ZW; Zhu X Front Immunol; 2022; 13():976107. PubMed ID: 36091006 [TBL] [Abstract][Full Text] [Related]
33. Relationships of N6-Methyladenosine-Related Long Non-Coding RNAs With Tumor Immune Microenvironment and Clinical Prognosis in Lung Adenocarcinoma. Zhao J; Lin X; Zhuang J; He F Front Genet; 2021; 12():714697. PubMed ID: 34777460 [No Abstract] [Full Text] [Related]
34. N6-methyladenosine-related lncRNAs identified as potential biomarkers for predicting the overall survival of Asian gastric cancer patients. Xu S; Chen W; Wang Y; Zhang Y; Xia R; Shen J; Gong X; Liang Y; Xu J; Tang H; Zhao T; Zhang Y; Chen T; Wang C BMC Cancer; 2022 Jul; 22(1):721. PubMed ID: 35778697 [TBL] [Abstract][Full Text] [Related]
35. Analysis of lncRNA-miRNA-mRNA interactions identified a novel biomarker LINC00657 to improve prognosis prediction of papillary thyroid carcinoma. Li S; Wang M; Liu B; Lv Y; Man J; Liang M; Qiao H Int Immunopharmacol; 2024 Aug; 137():112432. PubMed ID: 38865751 [TBL] [Abstract][Full Text] [Related]
36. Analysis of m6A-Related lncRNAs for Prognosis Value and Response to Immune Checkpoint Inhibitors Therapy in Hepatocellular Carcinoma. Wang Y; Li N; Tian D; Zhou CW; Wang YH; Yang C; Zeng MS Cancer Manag Res; 2021; 13():6451-6471. PubMed ID: 34429653 [TBL] [Abstract][Full Text] [Related]
37. Role of a lipid metabolism-related lncRNA signature in risk stratification and immune microenvironment for colon cancer. Lin Y; Xiao Y; Liu S; Hong L; Shao L; Wu J BMC Med Genomics; 2022 Oct; 15(1):221. PubMed ID: 36280825 [TBL] [Abstract][Full Text] [Related]
38. Identification of ferroptosis genes in immune infiltration and prognosis in thyroid papillary carcinoma using network analysis. Lin R; Fogarty CE; Ma B; Li H; Ni G; Liu X; Yuan J; Wang T BMC Genomics; 2021 Jul; 22(1):576. PubMed ID: 34315405 [TBL] [Abstract][Full Text] [Related]
39. Identification and validation of a seven m6A-related lncRNAs signature predicting prognosis of ovarian cancer. Song Y; Qu H BMC Cancer; 2022 Jun; 22(1):633. PubMed ID: 35676619 [TBL] [Abstract][Full Text] [Related]